Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective
J Cell Mol Med. 2023 Oct 17. doi: 10.1111/jcmm.17993. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is a heterogeneous neurodegenerative disease with multifaceted neuropathological disorders. AD is characterized by intracellular accumulation of phosphorylated tau proteins and extracellular deposition of amyloid beta (Aβ). Various protease enzymes, including neprilysin (NEP), are concerned with the degradation and clearance of Aβ. Indeed, a defective neuronal clearance pathway due to the dysfunction of degradation enzymes might be a possible mechanism for the accumulation of Aβ and subsequent progression of AD n...
Source: J Cell Mol Med - October 17, 2023 Category: Molecular Biology Authors: Naif H Ali Hayder M Al-Kuraishy Ali I Al-Gareeb Saud A Alnaaim Athanasios Alexiou Marios Papadakis Asmaa A Khalifa Hebatallah M Saad Gaber El-Saber Batiha Source Type: research
Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective
J Cell Mol Med. 2023 Oct 17. doi: 10.1111/jcmm.17993. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is a heterogeneous neurodegenerative disease with multifaceted neuropathological disorders. AD is characterized by intracellular accumulation of phosphorylated tau proteins and extracellular deposition of amyloid beta (Aβ). Various protease enzymes, including neprilysin (NEP), are concerned with the degradation and clearance of Aβ. Indeed, a defective neuronal clearance pathway due to the dysfunction of degradation enzymes might be a possible mechanism for the accumulation of Aβ and subsequent progression of AD n...
Source: Molecular Medicine - October 17, 2023 Category: Molecular Biology Authors: Naif H Ali Hayder M Al-Kuraishy Ali I Al-Gareeb Saud A Alnaaim Athanasios Alexiou Marios Papadakis Asmaa A Khalifa Hebatallah M Saad Gaber El-Saber Batiha Source Type: research
Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective
J Cell Mol Med. 2023 Oct 17. doi: 10.1111/jcmm.17993. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is a heterogeneous neurodegenerative disease with multifaceted neuropathological disorders. AD is characterized by intracellular accumulation of phosphorylated tau proteins and extracellular deposition of amyloid beta (Aβ). Various protease enzymes, including neprilysin (NEP), are concerned with the degradation and clearance of Aβ. Indeed, a defective neuronal clearance pathway due to the dysfunction of degradation enzymes might be a possible mechanism for the accumulation of Aβ and subsequent progression of AD n...
Source: J Cell Mol Med - October 17, 2023 Category: Molecular Biology Authors: Naif H Ali Hayder M Al-Kuraishy Ali I Al-Gareeb Saud A Alnaaim Athanasios Alexiou Marios Papadakis Asmaa A Khalifa Hebatallah M Saad Gaber El-Saber Batiha Source Type: research
Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective
J Cell Mol Med. 2023 Oct 17. doi: 10.1111/jcmm.17993. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is a heterogeneous neurodegenerative disease with multifaceted neuropathological disorders. AD is characterized by intracellular accumulation of phosphorylated tau proteins and extracellular deposition of amyloid beta (Aβ). Various protease enzymes, including neprilysin (NEP), are concerned with the degradation and clearance of Aβ. Indeed, a defective neuronal clearance pathway due to the dysfunction of degradation enzymes might be a possible mechanism for the accumulation of Aβ and subsequent progression of AD n...
Source: Molecular Medicine - October 17, 2023 Category: Molecular Biology Authors: Naif H Ali Hayder M Al-Kuraishy Ali I Al-Gareeb Saud A Alnaaim Athanasios Alexiou Marios Papadakis Asmaa A Khalifa Hebatallah M Saad Gaber El-Saber Batiha Source Type: research
Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP ‐HF registry
ConclusionsAmong patients with HF and at least one ‘I NEED HELP’ marker for advanced HF, left ventricular EF is still of prognostic value. (Source: ESC Heart Failure)
Source: ESC Heart Failure - October 17, 2023 Category: Cardiology Authors: Matteo Pagnesi,
Carlo Mario Lombardi,
Chiara Tedino,
Mauro Chiarito,
Davide Stolfo,
Luca Baldetti,
Marianna Adamo,
Filippo Cal ì,
Riccardo Maria Inciardi,
Daniela Tomasoni,
Ferdinando Loiacono,
Marta Maccallini,
Alessandro Villaschi,
Gaia Ga Tags: Original Article Source Type: research
Towards improved predictions of pharmacokinetics of transported drugs in hepatic impairment: insights from the extended clearance model
AbstractHepatic impairment (HI) moderately (< 5-fold) affects the systemic exposure (i.e. area under the plasma concentration-time curve, AUC) of drugs that are substrates of the hepatic sinusoidal organic anion transporting polypeptide (OATP) transporters and are excreted unchanged in the bile and/or urine. However, the effect of HI on their AUC is much greater (> 10-fold) for drugs that are also substrates of cytochrome P450 (CYP) 3A enzymes. Using the extended clearance model, through simulations, we identified the ratio of sinusoidal efflux clearance (CL) and the sum of metabolic and biliary CLs as importan...
Source: CPT: Pharmacometrics and Systems Pharmacology - October 14, 2023 Category: Drugs & Pharmacology Authors: Flavia Storelli,
Mayur K. Ladumor,
Xiaomin Liang,
Yurong Lai,
Paresh P. Chothe,
Osatohanmwen J. Enogieru,
Raymond Evers,
Jashvant D. Unadkat Tags: ARTICLE Source Type: research
The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension
ConclusionsSacubitril/valsartan not only provided superior BP reduction compared to olmesartan, it did so without adverse effects on glycemic control and lipid parameters in DM patients with primary hypertension. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 13, 2023 Category: Cardiology Source Type: research
Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
Conclusion: Our results demonstrate there is a considerable amount of comparative RWE for apixaban, rivaroxaban, and etanercept but limited comparative RWE for the other drugs set to undergo CMS price negotiations in 2026; additionally, our findings set up a number of next steps (e.g., risk of bias assessments) for further exploration of the available evidence base. Overall, CMS and manufacturers should consider proactively generating high-quality comparative RWE studies in the Medicare population to ensure that future price negotiations are based on robust evidence.PMID:37815792 | DOI:10.57264/cer-2023-0125 (Source: Journ...
Source: Journal of Comparative Effectiveness Research - October 10, 2023 Category: General Medicine Authors: Ashley Jaksa Patrick J Arena Nicolle Gatto Source Type: research
